Fly News Breaks for September 5, 2019
BSX
Sep 5, 2019 | 06:23 EDT
JPMorgan analyst Robbie Marcus reinstated coverage of Boston Scientific with an Overweight rating and $50 price target following a period of restriction. The analyst continues to see the company as a "best-in-class Large-Cap MedTech asset," with "many shots on goal" to support a multi-year premium organic sales growth trajectory of 7%-10% through 2023.
News For BSX From the Last 2 Days